STOCK TITAN
  1. Home
  2. Sec-filings
  3. EDSA
  4. [Form 4] Edesa Biotech, Inc. Insider Trading Activity

Edesa Biotech (EDSA) CEO receives 2,578-share restricted stock grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Nijhawan Pardeep reported acquisition or exercise transactions in this Form 4 filing.

Edesa Biotech, Inc. reported that Chief Executive Officer Pardeep Nijhawan received a grant of 2,578 restricted share units on April 1, 2026, which vested in full upon grant under the 2019 Equity Incentive Compensation Plan. Following this award, he directly holds 631,391 common shares, with additional indirect holdings reported through several affiliated entities and a family trust.

Positive

  • None.

Negative

  • None.
Insider Nijhawan Pardeep
Role Chief Executive Officer
Type Security Shares Price Value
Grant/Award Common Shares 2,578 $0.00 --
holding Common Shares -- -- --
holding Common Shares -- -- --
holding Common Shares -- -- --
holding Common Shares -- -- --
Holdings After Transaction: Common Shares — 631,391 shares (Direct); Common Shares — 402,702 shares (Indirect, Held by Pardeep Nijhawan Medicine Professional Corporation)
Footnotes (1)
  1. Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Reporting Person is a co-trustee of The New Nijhawan Family Trust 2015. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Restricted share unit grant 2,578 units Award to CEO on April 1, 2026
Award price per share $0.0000 per share Restricted share unit grant
Direct holdings after grant 631,391 shares CEO common shares after April 1, 2026 transaction
Indirect holdings – Pardeep Nijhawan Medicine Professional Corporation 402,702 shares Common shares held indirectly
Indirect holdings – New Nijhawan Family Trust 2015 32,609 shares Common shares held indirectly
Indirect holdings – The Digestive Health Clinic Inc. 32,013 shares Common shares held indirectly
Indirect holdings – 1968160 Ontario Inc. 53,104 shares Common shares held indirectly
restricted share units financial
"Reflects a grant of restricted share units, which vested in full upon grant"
Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.
2019 Equity Incentive Compensation Plan financial
"vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan"
pecuniary interest financial
"disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein"
beneficial ownership financial
"shall not be deemed an admission of beneficial ownership of all of the reported shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
wholly-owned financial
"Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person"
A wholly-owned business is one that is 100% owned by another company, meaning the parent holds all shares and controls decisions. For investors, this matters because the parent company must include the wholly-owned business’s results and liabilities in its own financial picture, so any profits, losses or risks from that unit directly affect the parent’s value—like owning an entire rental property rather than sharing it with partners.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Nijhawan Pardeep
(Last)(First)(Middle)
C/O EDESA BIOTECH INC.
100 SPY COURT
(Street)
MARKHAML3R 5H6
(City)(State)(Zip)
ONTARIO, CANADA
(Country)		2. Issuer Name and Ticker or Trading Symbol
Edesa Biotech, Inc. [ EDSA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Shares04/01/2026A2,578(1)A$0(1)631,391D
Common Shares402,702IHeld by Pardeep Nijhawan Medicine Professional Corporation(2)
Common Shares32,609IHeld by The New Nijhawan Family Trust 2015(3)
Common Shares32,013IHeld by The Digestive Health Clinic Inc.(2)
Common Shares53,104IHeld by 1968160 Ontario Inc.(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.
2. Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
3. Reporting Person is a co-trustee of The New Nijhawan Family Trust 2015. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
/s/ Peter J. Weiler, Attorney-in-Fact for Pardeep Nijhawan04/10/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Edesa Biotech (EDSA) report for its CEO?

Edesa Biotech reported that CEO Pardeep Nijhawan received 2,578 restricted share units on April 1, 2026. These units vested immediately and increased his direct common share holdings to 631,391, according to the company’s 2019 Equity Incentive Compensation Plan.

How many Edesa Biotech shares does CEO Pardeep Nijhawan hold after this Form 4?

After the April 1, 2026 grant, Pardeep Nijhawan directly holds 631,391 common shares of Edesa Biotech. The filing also lists additional indirect holdings through several corporations and a family trust, where his beneficial ownership is disclaimed except for his pecuniary interest.

What is the size and nature of the equity award to Edesa Biotech’s CEO?

The CEO received 2,578 restricted share units with a reported price of $0.0000 per unit. A footnote explains this reflects a grant under Edesa Biotech’s 2019 Equity Incentive Compensation Plan and that the units vested in full immediately upon grant.

Does the Edesa Biotech CEO’s Form 4 include indirect share holdings?

Yes. The Form 4 lists indirect holdings in entities such as Pardeep Nijhawan Medicine Professional Corporation and The New Nijhawan Family Trust 2015. The CEO disclaims beneficial ownership of these securities except to the extent of his pecuniary interest in those entities.

Is the April 1, 2026 Edesa Biotech Form 4 a market purchase or sale?

No, the primary transaction is a compensation-related grant coded “A” for an award or other acquisition. It represents 2,578 restricted share units that vested upon grant, rather than an open-market purchase or sale of Edesa Biotech common shares.

What compensation plan governed the CEO’s equity grant at Edesa Biotech?

The grant of 2,578 restricted share units to Edesa Biotech’s CEO was made under the company’s 2019 Equity Incentive Compensation Plan. The footnote states that these restricted share units vested in full upon grant, indicating an immediately realized equity award.